Daré Bioscience announced that its President and CEO, Sabrina Martucci Johnson, will participate in a Virtual Investor Closing Bell event on Tuesday, July 14, 2026, at 4:00 PM ET. She will provide a corporate overview highlighting the recent launch of FloraSync LF5™, the company’s strategy for building its commercial business while advancing its women’s health pipeline, and key milestones for long-term growth. The discussion will also cover the company’s approach to capital allocation, commercialization, and execution. A live question and answer session with audience participants will follow, and a webcast replay will be available on the company’s website for 90 days.
Dare Bioscience IncCEO participation in investor event and corporate overview may attract investor interest and support capital allocation strategy.